Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients

Expert Review of Proteomics

Volumn 6, Issue 1, 2009, Pages 43-60

  Mannello, Ferdinando ^a   Medda, Virginia ^a   Tonti, Gaetana A ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Breast cancer; Diagnosis; Nipple aspirate fluid; Prognosis; Protein; Proteinase; Proteomics; Tumor marker

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA LACTALBUMIN; APOLIPOPROTEIN D; ASPARTIC PROTEINASE; CARCINOEMBRYONIC ANTIGEN; ERYTHROPOIETIN; GROWTH FACTOR; LACTATE DEHYDROGENASE; PEPTIDE HORMONE; PHOSPHOLIPASE A2; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TUMOR ANTIGEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RISK; GEL ELECTROPHORESIS; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NIPPLE ASPIRATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

BODY FLUIDS; BREAST; BREAST NEOPLASMS; FEMALE; HEALTH; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS;

EID: 60549106219     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.6.1.43     Document Type: Review

References (125)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Gralow J, Ozols RF, Bajorin DF et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 26(2), 313-325 (2008).
3. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr. Relat. Cancer 12(2), 185 -213 (2005).
4. Petrakis NL. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid. Cancer Epidemiol. Biomarkers Prev. 2(1), 3-10 (1993).
5. Sauter ER. Analysis of nipple aspirate fluid for diagnosis of breast cancer: an alternative to invasive biopsy. Expert Rev. Mol. Diagn. 5(6), 873-881 (2005).
6. Mannello F. Analysis of the intraductal microenvironment for the early diagnosis of breast cancer: identification of biomarkers in nipple-aspirate fluids. Expert Opin. Med. Diagn. 2(11), 1221-1231 (2008).
7. Papanicolaou GN, Holmquist DG, Bader GM, Falk EA. Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer 11, 377-409 (1958).
8. Klein P, Glaser E, Grogan L et al. Biomarker assays in nipple aspirate fluid. Breast J. 7(6), 378-387 (2001).
9. Dua RS, Isacke CM, Gui GP. The intraductal approach to breast cancer biomarker discovery. J. Clin. Oncol. 24(7), 1209-1216 (2006).
10. Petrakis NL. Nipple aspirate fluid in epidemiologic studies of breast disease. Epidemiol. Rev. 15(1), 188-195 (1993).
11. Sartorius OW. Breast fluid cells help in early cancer detection. JAMA 224, 823-827 (1973).
12. King EB, Chew KL, Petrakis NL, Ernster VL. Nipple aspirate cytology for the study of breast cancer precursors. J. Natl Cancer Inst. 71(6), 1115-1121 (1983).
13. Malatesta M, Mannello F, Bianchi G, Sebastiani M, Gazzanelli G. Biochemical and ultrastructural features of human milk and nipple aspirate fluids. J. Clin. Lab. Anal. 14(6), 330-335 (2000).
14. Mannello F, Tonti GA, Qin W, Zhu W, Sauter ER. Do nipple aspirate fluid epithelial cells and their morphology predict breast cancer development? Breast Cancer Res. Treat. 102(1), 125-127 (2007).
15. LaKind JS, Wilkins AA, Bates MN. Human breast biomonitoring and environmental chemicals: use of breast tissues and fluids in breast cancer etiologic research. J. Expo. Sci. Environ. Epidemiol. 17(6), 525 -540 (2007).
16. Petrakis NL. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res. Treat. 8(1), 7-19 (1986).
17. Petrakis NL, Mason L, Lee R, Sugimoto B, Pawson S, Catchpool F. Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration. J. Natl Cancer Inst. 54(4), 829-834 (1975).
18. Wrensch MR, Petrakis NL, Gruenke LD et al. Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review. Breast Cancer Res. Treat. 15(1), 39-51 (1990).
19. Mannello F, Tonti GA, Canestrari F. Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer aetiology. Genes Nutr. 3, 77-85 (2008).
20. Sauter ER, Ross E, Daly M et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br. J. Cancer 76(4), 494-501 (1997).
21. Petrakis NL, Barnes S, King EB et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 5(10), 785-794 (1996).
22. Sauter ER, Winn JN, Dale PS, Wagner-Mann C. Nipple aspirate fluid color is associated with breast cancer. Cancer Detect. Prev. 30(4), 322-328 (2006).
23. Cooper AP. The Anatomy and Diseases of the Breast. Lea and Blanchard, PA, USA (1845).
24. Lonnerdal B. Human milk proteins: key components for the biological activity of human milk. Adv. Exp. Med. Biol. 554, 11-25 (2004).
25. Piper KM, Berry CA, Cregan MD. The bioactive nature of human breastmilk. Breastfeed. Rev. 15(3), 5-10 (2007).
26. Lopez Alvarez MJ. Proteins in human milk. Breastfeed. Rev. 15(1), 5-16 (2007). 27 Adair FE, Bagg HJ. Breast stasis as the cause of mammary cancer. Int. Clin. 4, 19-26 (1925).
27. Sartorius OW. The biochemistry of breast cyst fluids and duct secretions. Breast Cancer Res. Treat. 35(3), 255-266 (1995).
28. Wrensch MR, Petrakis NL, Miike R et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J. Natl Cancer Inst. 93(23), 1791-1798 (2001).
29. Sanchez LM, Vizoso F, Diez-Itza I, Lopez-Otin C. Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res. 52(1), 95 -100 (1992).
30. Mannello F, Tonti GA, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res. Treat. 97(2), 115-129 (2006).
31. Vizoso F, Sánchez LM, Díez-Itza I, Luz Lamelas M, López-Otín C. Factors affecting protein composition of breast secretions from nonlactating women. Breast Cancer Res. Treat. 23(3), 251-258 (1992).
32. Thean ET, Toh BH. Serum human α-lactalbumin as a marker for breast cancer. Br. J. Cancer 61(5), 773-775 (1990).
33. Varnum SM, Covington CC, Woodbury RL et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res. Treat. 80(1), 87-97 (2003).
34. Huang Y, Nagamani M, Anderson KE et al. A strong association between body fat mass and protein profiles in nipple aspirate fluid of healthy premenopausal non- lactating women. Breast Cancer Res. Treat. 104(1), 57-66 (2007).
35. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin. Cancer Res. 10(22), 7500-7510 (2004).
36. Marx J. Cancer research. Inflammation and cancer: the link grows stronger. Science 306(5698), 966-968 (2004).
37. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J. Epidemiol. Community Health 61(9), 824-833 (2007).
38. Lithgow D, Nyamathi A, Elashoff D, Martinez-Maza O, Covington C. C-reactive protein in nipple aspirate fluid: relation to women's health factors. Nurs. Res. 55(6), 418-425 (2006).
39. Lithgow D, Nyamathi A, Elashoff D, Martinez-Maza O, Covington C. C-reactive protein in nipple aspirate fluid associated with Gail model factors. Biol. Res. Nurs. 9(2), 108-116 (2007).
40. Duche JC, Urien S, Simon N, Malaurie E, Monnet I, Barre J. Expression of the genetic variants of human a-1-acid glycoprotein in cancer. Clin. Biochem. 33(3), 197-202 (2000).
41. Mohanty AK, Singh G, Paramasivam M et al. Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP- 40) secreted during involution. J. Biol. Chem. 278(16), 14451-14460 (2003).
42. Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opin. Ther. Targets 11(2), 219-234 (2007).
43. Qin W, Zhu W, Schlatter L et al. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int. J. Cancer 121(7), 1536-1542 (2007).
44. Roslind A, Knoop AS, Jensen MB et al. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res. Treat. 112(2), 275-285 (2008).
45. Petrakis NL, Lowenstein JM, Wiencke JK et al. Gross cystic disease fluid protein in nipple aspirates of breast fluid of Asian and non-Asian women. Cancer Epidemiol. Biomarkers Prev. 2(6), 573-579 (1993).
46. Sapino A, Cassoni P, Bussolati G. Gross cystic disease fluid protein (GCDFP-15) in the breast: past and present. J. Biol. Regul. Homeost. Agents 14(4), 259-262 (2000).
47. Mannello F, Marcheggiani F, Gazzanelli G. Breast cancer diagnosis by lactate dehydrogenase isozymes in nipple discharge. Cancer 76(1), 152-154 (1995).
48. Liaudet-Coopman E, Beaujouin M, Derocq D et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 237(2), 167-179 (2006).
49. Sanchez LM, Ferrando AA, Diez-Itza I, Vizoso F, Ruibal A, Lopez-Otin C. Cathepsin D in breast secretions from women with breast cancer. Br. J. Cancer 67(5), 1076-1081 (1993).
50. Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol. Biomarkers Prev. 13(6), 928-935 (2004).
51. Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT. Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol. Biomarkers Prev. 15(1), 39-44 (2006).
52. Palioura s M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 249(1), 61-79 (2007).
53. Diamandis EP, Yousef GM, Soosaipillai AR et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/ neurosin) and preliminary clinical applications. Clin. Biochem. 33(5), 369-375 (2000).
54. Black MH, Magklara A, Obiezu C et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br. J. Cancer 82(2), 361-367 (2000).
55. Sauter ER, Welch T, Magklara A, Klein G, Diamandis EP. Ethnic variation in kallikrein expression in nipple aspirate fluid. Int. J. Cancer 100(6), 678-682 (2002).
56. Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer 108(4), 588-591 (2004).
57. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect. Prev. 31(1), 50-58 (2007).
58. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (review). Oncol. Rep. 14(1), 105-112 (2005).
59. Qin W, Zhu W, Wagner-Mann C, Folk W, Sauter ER. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer. Cancer J. 9(4), 293-301 (2003).
60. Qin W, Zhu W, Wagner-Mann C, Sauter ER. Nipple aspirate fluid expression of u rokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease. Ann. Surg. Oncol. 10(8), 948-953 (2003).
61. Qin W, Zhu W, Hewett JE et al. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer. BMC Cancer 15(8), 298 (2008).
62. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets 5(4), 285-298 (2005).
63. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Patents Anticancer Drug Discov. 1(1), 91-103 (2006).
64. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin. Exp. Metastasis 24(8), 647-656 (2007).
65. Mannello F, Tonti G A. Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int. J. Cancer 121(1), 216-218 (2007).
66. Mannello F, Sebastiani M. Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin. Chem. 49(9), 1546-1550 (2003).
67. Mannello F, Qin W, Zhu W, Fabbri L, Tonti GA, Sauter ER. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res. Treat. 111(2), 209-218 (2007).
68. Brash AR. Arachidonic acid as a bioactive molecule. J. Clin. Invest 107(11), 1339-1345 (2001).
69. Mannello F, Tonti GA, Pagliarani S et al. The 8-epimer of prostaglandin F(2α), a ma rker of lipid perox idation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer. Int. J. Cancer 120(9), 1971-1976 (2007).
70. Boudreau N, Myers C. Breast cancer- induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 5(3), 140-146 (2003).
71. Liu Y, Wang JL, Chang H, Barsky SH, Nguyen M. Breast-cancer diagnosis with nipple fluid bFGF. Lancet 356(9229), 567 (2000).
72. Hsiung R, Zhu W, Klein G et al. High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer J. 8(4), 303-310 (2002).
73. Sartippour MR, Zhang L, Lu M, Wang HJ, Brooks MN. Nipple fluid basic fibroblast growth factor in patients with breast cancer. Cancer Epidemiol. Biomarkers Prev. 14(12), 2995-2998 (2005).
74. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122(3), 467-481 (1965).
75. Troccoli R, Stella F, Stella C et al. [Carcinoembryonic antigen in a review of cases in the literature]. Quad. Sclavo. Diagn. 23(3), 233-245 (1987).
76. Kahana L, Bartal AH, Yechieli H, Guttman I, Sheinfeld M. Carcinoembryonic-like substance in breast fluid discharge in benign and malignant breast disease and in milk of lactating women. Isr. J. Med. Sci. 17(11), 1035-1040 (1981).
77. Inaji H, Koyama H, Motomura K et al. ErbB-2 protein levels in nipple discharge: role in diagnosis of early breast cancer. Tumour Biol. 14(5), 271-278 (1993).
78. Foretova L, Garber JE, Sadowsky NL et al. Carcinoembryonic antigen in breast nipple aspirate fluid. Cancer Epidemiol. Biomarkers Prev. 7(3), 195-198 (1998).
79. Imayama S, Mori M, Ueo H et al. Presence of elevated carcinoembryonic antigen on absorbent disks applied to nipple area of breast carcinoma patients. Cancer 78 (6), 1229-1234 (1996).
80. Zhao Y, Verselis SJ, Klar N et al. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J. Clin. Oncol. 19(5), 1462-1467 (2001).
81. Lee A, Kim Y, Han K, Kang CS, Jeon HM, Shim SI. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine- needle aspiration fluid of breast. Arch. Pathol. Lab. Med. 128(11), 1251-1256 (2004).
82. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev. Mol. Diagn. 8(4), 417-434 (2008).
83. Kuerer HM, Thompson PA, Krishnamurthy S et al. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin. Cancer Res. 9(2), 601-605 (2003).
84. Mannello F, Gazzanelli G. Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res. 3(4), 238-243 (2001).
85. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 54(10), 1600-1607 (2008).
86. Mannello F, Malatesta M, Sebastiani M, Battistelli S, Gazzanelli G. Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin. Chem. 45(12), 2263-2266 (1999).
87. Sauter ER, Daly M, Linahan K et al. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 5(12), 967-970 (1996).
88. Sauter ER, Chervoneva I, Diamandis A, Khosravi JM, Litwin S, Diamandis EP. Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. Cancer Detect. Prev. 26(2), 149-157 (2002).
89. Sauter ER, Babb J, Daly M et al. Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol. Biomarkers Prev. 7(4), 315-320 (1998).
90. Sauter ER, Tichansky DS, Chervoneva I, Diamandis EP. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. Environ. Health Perspect. 110(3), 241-246 (2002).
91. Mitchell G, Sibley PE, Wilson AP, Sauter E, A'Hern R, Eeles RA. Prostate-specific antigen in nipple aspiration fluid: menstrual cycle variability and correlation with serum prostate-specific antigen. Tumour Biol. 23(5), 287-297 (2002).
92. Sauter ER, Garofalo C, Hewett J, Hewett JE, Morelli C, Surmacz E. Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer. Horm. Metab. Res. 36(5), 336-340 (2004).
93. Rose DP. Hormones and growth factors in nipple aspirates from normal women and benign breast disease patients. Cancer Detect. Prev. 16(1), 43-51 (1992).
94. Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J. Clin. Endocrinol. Metab. 90(3), 1686-1691 (2005).
95. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur. J. Haematol. 78(3), 183-205 (2007).
96. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin. Cancer Res. 12(2), 332-339 (2006).
97. Mannello F, Fabbri L, Ciandrini E, Tonti GA. Increased levels of erythropoietin in nipple aspirate fluid and in ductal cells from breast cancer patients. Cell. Oncol. 30(1), 51-61 (2008).
98. Mannello F, Tonti GA. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Oncologist 13(7), 761-768 (2008).
99. Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 95(11), 2276-2282 (2002).
100. Pawlik TM, Hawke DH, Liu Y et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 6, 68 (2006).
101. Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J. Mammary Gland Biol. Neoplasia 7(4), 433-440 (2002).
102. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3(4), 367-378 (2004).
103. Paweletz CP, Trock B, Pennanen M et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers 17(4), 301-307 (2001).
104. Noble J, Dua RS, Locke I, Eeles R, Gui GP, Isacke CM. Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women. Breast Cancer Res. Treat. 104(2), 191-196 (2007).
105. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur. J. Cancer 43(16), 2315-2320 (2007).
106. Pawlik TM, Fritsche H, Coombes KR et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res. Treat. 89(2), 149-157 (2005).
107. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC. Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br. J. Cancer 86(9), 1440-1443 (2002).
108. Sauter ER, Shan S, Hewett JE, Speckman P, Du Bois GC. Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. Int. J. Cancer 114(5), 791-796 (2005).
109. Li J, Zhao J, Yu X et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 11(23), 8312-8320 (2005).
110. Kuerer HM, Coombes KR, Chen JN et al. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. Surgery 136(5), 1061-1069 (2004).
111. He J, Gornbein J, Shen D et al. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int. J. Oncol. 30(1), 145-154 (2007).
112. Carr KM, Rosenblatt K, Petricoin EF, Liotta LA. Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum. Genomics 1(2), 134-140 (2004).
113. Zangar RC, Varnum SM, Covington CY, Smith RD. A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays. Dis. Markers 20(3), 135-148 (2004).
114. Chotiner HC, Adams HR, Spiekerman AM, Gilliland PF, Newmark SR. Lactose and casein content of nonpuerperal breast secretion. J. Reprod. Med. 22(5), 267-270 (1979).
115. Petrakis NL, Doherty M, Lee R et al. Immunoglobulin levels in breast fluids of women with breast cancer. Clin. Immunol. Immunopathol. 7(3), 386-393 (1977).
116. Yap PL, Miller WR, Humeniuk V, Pryde EA, Mirtle CL, McClelland DB. Milk protein concentrations in the mammary secretions of non-lactating women.J. Reprod. Immunol. 3(1), 49-58 (1981).
117. Shao ZM, Liu Y, Nguyen M. The role of the breast ductal system in the diagnosis of cancer (review). Oncol. Rep. 8(1), 153-156 (2001).
118. Connolly JM, Rose DP. Epidermal growth factor-like proteins in breast fluid and human milk. Life Sci. 42(18), 1751-1756 (1988).
119. Gann P, Chatterton R, Vogelsong K, Dupuis J, Ellman A. Mitogenic growth factors in breast fluid obtained from healthy women: evaluation of biological and extraneous sources of variability. Cancer Epidemiol. Biomarkers Prev. 6(6), 421-428 (1997).
120. Foretova L, Garber JE, Sadowsky NL, Verselis SJ, Li FP. Prostate-specific antigen in nipple aspirate. Lancet 347(9015), 1631 (1996).
121. Kumar SR, Sauter ER, Quinn TP, Deutscher SL. Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection. Clin. Cancer Res. 11(19 Pt 1), 6868-6871 (2005).
122. Wynder EL, Hill P. Prolactin, oestrogen, and lipids in breast fluid. Lancet 2(8043), 840-842 (1977).
123. Wynder EL, Hill P, Laakso K, Littner R, Kettunen K. Breast secretion in Finnish women: a metabolic epidemiologic study. Cancer 47(6), 1444-1450 (1981).
124. Rose DP. Hormones in breast fluid. Breast Cancer Res. Treat. 8(1), 25-28 (1986).
125. Rose DP, Berke B, Cohen LA, Lahti H. A comparison of serum and breast duct fluid-immunoassayable prolactin and growth hormone with bioassayable lactogenic hormones in healthy women and patients with cystic breast disease. Cancer 60(11), 2761-2765 (1987).